Thebaine Market- by Applications Oxymorphone, Nalbuphine, Naltrexone

Launch of new campaigns to promote drug abuse treatment is expected to be a major driver for growth of global thebaine market. For instance, in 2018, Trump administration i.e. White House Administration launched a multi-million dollar opioid awareness campaign for young adults. This campaign aims at curbing addition of opioid among young population. This campaign also spreads awareness by sharing true life stories of drug addicts to educate teens as well as young adults. According to a survey conducted by Substance Abuse and Mental health Services administration in 2018, opioid crisis kills an average of 116 Americans annually. Such government organized campaigns and high number of people dying due to opioid crisis are expected to encourage people to get rid of substance abuse addiction using different treatments available to live a healthy life.

North America is expected to hold a dominant position in global thebaine market due to robust pipeline. For instance, New York state Psychiatric Institute’s drug Pioglitazone (oxycodone) has completed Phase 2 clinical trials in 2016. Pioglitazone (oxycodone) is used in the treatment of drug abuse (Opioid Abuse). Launch of new drugs is expected to fuel theabine market growth. For instance, in 2017, ANI Pharmaceuticals Inc., a specialty pharmaceutical company, launched Oxycodone Hydrochloride Oral Solution 100m/5ml. Oxycodone Hydrochloride Oral Solution is used to treat acute pain.

Europe thebaine market is expected to witness significant growth due to robust pipeline of thebaine drugs. For instance, University children’s hospital’s drug Nalbuphine completed Phase 1 clinical trials in 2017. Nalbuphine is used to treat pain related to intravenous injections especially for used in infants.

Launch of new generic drugs is expected to support Asia Pacific thebaine market growth. For instance, in 2017, Daiichi Sankyo Company Ltd., a global pharmaceutical company launched generic version of oxycodone immediate release formulation. Oxycodone immediate release formulation, which is used to treat cancer pain.

Click To Continue Reading On Thebaine Market

Robust pipeline of thebaine drugs is expected to drive thebaine market growth. For instance, in 2017, National institute of Health and Welfare’s drug Naloxone hydrochloride 20mg/ml completed phase 2 clinical trials. Naloxone hydrochloride is used to treat opioid drug abuse.

University of British Coloumbia’s drug Naloxone completed phase 2 in 2016. Naloxone is used to treat pain related to post-operation process as well as acute pain treatment. Trevi Therapeutics’s drug Albuphine Hcl ER tablets 90 mg has completed phase 2 clinical trials in 2016. Albuphine HCl ER tablets 90 mg is used to treat Prurigo Nodularis, which is a nodular skin disease.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702

Reset Password